These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29967338)

  • 1. Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats.
    Ito Y; Ohno K; Morikawa Y; Tomizawa A; Mizuno M; Sugidachi A
    Sci Rep; 2018 Jul; 8(1):9955. PubMed ID: 29967338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
    Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
    Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
    Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
    Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
    PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets Express Activated P2Y
    Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
    Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet effects of caffeic acid due to Ca(2＋) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
    Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
    J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling.
    Irfan M; Jeong D; Kwon HW; Shin JH; Park SJ; Kwak D; Kim TH; Lee DH; Park HJ; Rhee MH
    Vascul Pharmacol; 2018 Oct; 109():45-55. PubMed ID: 29890296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
    Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
    Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function.
    Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
    Thromb Haemost; 2010 Jun; 103(6):1210-7. PubMed ID: 20431852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p-Terphenyl curtisian E inhibits in vitro platelet aggregation via cAMP elevation and VASP phosphorylation.
    Kamruzzaman SM; Yayeh T; Ji HD; Park JY; Kwon YS; Lee IK; Kim S; Oh SH; Kim SD; Roh SS; Yun BS; Rhee MH
    Vascul Pharmacol; 2013; 59(3-4):83-9. PubMed ID: 23872194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
    Yamamoto H; Takahashi K; Watanabe H; Yoshikawa Y; Shirakawa R; Higashi T; Kawato M; Ikeda T; Tabuchi A; Morimoto T; Kita T; Horiuchi H
    Circ J; 2008 Nov; 72(11):1844-51. PubMed ID: 18832777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
    Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
    Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
    Blindt R; Stellbrink K; de Taeye A; Müller R; Kiefer P; Yagmur E; Weber C; Kelm M; Hoffmann R
    Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.